Our data suggest that treatment of patients with TP53-deficient hematological neoplasms will require a relatively higher dose of infused CAR T-cells at a given tumor load (e.g., minimal residual disease) to achieve complete remissions—an approach, which has been pursued with other malignancies stratified as a high-risk disease (Brudno et al, 2018). This evidence concerns the gene TP53 and hematopoietic and lymphoid system neoplasm.